Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue SUPPL. 1, 2003, Pages 43-47

  Paladino, Joseph A ^a,b   Callen, Wendy A ^a  

^a CPL Associates LLC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Benchmarking; Fluoroquinolones; Pharmacodynamics; Pharmacoeconomics

Indexed keywords

ANTIINFECTIVE AGENT; CEFTRIAXONE; CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; COST EFFECTIVENESS ANALYSIS; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG POTENCY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRACTICE GUIDELINE; QUALITY CONTROL; RESPIRATORY TRACT INFECTION; REVIEW;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BENCHMARKING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0038778584     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg211     Document Type: Review

References (34)

1. Liss, R. H. & Batchelor, F. R. (1987). Economic evaluations of antibiotic use and resistance - a perspective: report of Task Force 6. Reviews of Infectious Diseases 9, Suppl. 3, S297-312.
2. Rubin, M. A. & Samore, M. H. (2002). Antimicrobial use and resistance. Current Infectious Disease Reports 4, 491-7.
3. Edberg, S. C. (1981). Methods of quantitative microbiological analyses that support the diagnosis, treatment, and prognosis of human infection. Critical Reviews in Microbiology 8, 339-97.
4. Pickerill, K. E., Paladino, J. A. & Schentag, J. J. (2000). Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 20, 417-28.
5. Paladino, J. A. (2001). Is more than one quinolone needed in clinical practice? Annals of Pharmacotherapy 35, 1085-95.
6. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-10.
7. Schentag, J. J., Smith, I. L., Swanson, D. J., DeAngelis, C., Fracasso, J. E., Vari, A. et al. (1984). Role for dual individualization with cefmenoxime. American Journal of Medicine 77, Suppl. 6A, 43-50.
8. Nix, D. E., Sands, M. F., Peloquin, C. A., Vari, A. J., Cumbo, T. J., Vance, J. W. et al. (1987). Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. American Journal of Medicine 82, Suppl. 4A, 352-6.
9. Schentag, J. J., Nix, D. E. & Adelman, M. H. (1991). Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Annals of Pharmacotherapy 25, 1050-7.
10. Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
11. Madaras-Kelly, K. J., Ostergaard, B. E., Hovde, L. B. & Rotschafer, J. C. (1996). Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 40, 627-32.
12. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279, 125-9.
13. Hyatt, J. M., McKinnon, P. S., Zimmer, G. S. & Schentag, J. J. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clinical Pharmacokinetics 28, 143-60.
14. Vogelman, B. & Craig, W. A. (1986). Kinetics of antimicrobial activity. Journal of Pediatrics 108, 835-40.
15. Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H. et al. (1998). Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrobial Agents and Chemotherapy 42, 521-7.
16. Burgess, D. S. (1999). Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115, Suppl. 3, 19S-23.
17. Forrest, A., Chodosh, S., Amantea, M. A., Collins, D. A. & Schentag, J. J. (1997). Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 45-57.
18. Paladino, J. A. & Fell, R. E. (1994). Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Annals of Pharmacotherapy 28, 384-9.
19. Paladino, J. A., Zimmer, G. S. & Schentag, J. J. (1996). The economic potential of dual individualization methodologies. Pharmacoeconomics 10, 539-45.
20. Paladino, J. A., Sperry, H. E., Backes, J. M., Gelber, J. A., Serrianne, D. J., Cumbo T. J. et al. (1991). Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. American Journal of Medicine 91, 462-70.
21. Jensen, K. M. & Paladino, J. A. (1997). Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones. Pharmacoeconomics 11, 64-74.
22. Partsch, D. J. & Paladino, J. A. (1997). Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. Annals of Pharmacotherapy 31, 1137-45.
23. Walters, D. J., Solomkin, J. S. & Paladino, J. A. (1999). Cost effectiveness of ciprofloxacin plus metronidazole versus imipenemcilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics 16, 551-61.
24. Dresser, L. D., Niederman, M. S. & Paladino, J. A. (2001). Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 119, 1439-48.
25. Rifenburg, R. P., Paladino, J. A., Bhavnani, S. M., Haese, D. D. & Schentag, J. J. (1999). Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. American Journal of Health-System Pharmacy 56, 2217-23.
26. Patrick, M. S. (1992). Benchmarking-targeting 'best practices'. Healthcare Forum Journal 35, 71-2.
27. Bergman, R. (1994). Hitting the mark. Benchmarking: management tool in the quest for improved clinical quality. Hospital and Health Networks 68, 48, 50-1.
28. Witt, M. J. (2001). Improving group practice performance with benchmarking. Healthcare and Financial Management 55, 67-70.
29. Murphy, J. E. (2000). Using benchmarking data to evaluate and support pharmacy programs in health systems. American Journal of Health-System Pharmacy 57, Suppl. 2, S28-31.
30. Schentag, J. J., Paladino, J. A., Birmingham, M. C., Zimmer, G., Carr, J. R. & Hanson, S. C. (1995). Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. Journal of Pharmacy Technology 11, 203-10.
31. Rifenburg, R. P., Paladino, J. A., Hanson, S. C., Tuttle, J. A. & Schentag, J. J. (1996). Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. American Journal of Health-System Pharmacy 53, 2054-62.
32. Bhavnani, S. M., Paladino, J. A., Forrest, A., Collins, D. A. & Schentag, J. J. (1999). Association between fluoroquinolone expenditures and ciprofloxacin susceptibility of Pseudomonas aeruginosa among US hospitals. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 182, p. 734. American Society for Microbiology, Washington, DC, USA.
33. Jones, M. E., Staples, A. M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H. D. et al. (2000). Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study. Diagnostic Microbiology and Infectious Disease 37, 203-11.
34. Jones, M. E., Staples, A. M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H. D. et al. (2000) Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrobial Agents and Chemotherapy 44, 2645-52.